Skip to content
CityAM
Main navigation
Sign Up
  • News
    • Latest News
    • Property
    • Media
    • Technology
    • Retail and leisure
    • Transport and infrastructure
    • Law & professional services
    • Legal Notices
    • Banking
    • Politics
    • CFA Institute Talk
  • Markets & Economics
    • Markets & Economics News
    • Economics
    • Markets
    • The Trend Micro Cybersecurity Knowledge Hub
    • Talk Crypto
    • M&A Talk
  • Crypto A.M.
    • Crypto News
    • Crypto Magazine
    • Crypto AM Summit & Awards 2022
  • Opinion
    • Features
    • Letters
    • The City View
  • Money
    • Jobs and Money News
    • Personal Development
    • Jobs
    • Fintech
    • Money
    • Personal Finance
    • Nine smart ideas for improving your financial outlook
    • Warwick Business School
  • Unwind
    • Life & Style
    • Sport
    • The Punter
    • The Magazine
    • Travel
    • Sport Business
    • The Punter Podcast
    • Culture
    • Six Nations 2023
    • LIV Golf
    • Aramco Team Series
  • Impact A.M.
    • Impact A.M.
    • DiverCity Podcast
    • Partner Hubs
  • Latest Paper
  • Jobs
  • CityAM Awards 2023
  • Charity

AstraZeneca

  • AstraZeneca boss urges UK government to invest in medicines of the future

    November 10, 2022

    The chief of AstraZeneca has urged the UK government to invest in the medicines of the future, as the regulatory environment for pharma in the US grows tougher. With the UK’s upcoming budget, CEO Pascal Soriot called on the government to protect the funding for innovative treatments as the long-term outlook for the healthcare industry [...]

  • Investors bet on AstraZeneca’s experimental breast cancer drug following positive trial

    October 26, 2022

    Shares rose in AstraZeneca today on the back of progress made with its breast cancer treatment, which combines its older Faslodex drug with a new experimental offering. Breast cancer is the most common cancer in the world, with around 2.3 million patients diagnosed with the disease in 2020. It follows a disappointing result in a [...]

  • AstraZeneca asthma drug misses key marker in late-stage trial

    October 25, 2022

    AstraZeneca’s asthma drug failed to significantly improve difficulties swallowing in a late-stage trial, the pharmaceutical giant announced today. The drug, called Fasenra, met just one of two main goals of a stage III study assessing the treatment’s benefits in a chronic allergic condition that causes difficulty in swallowing. The condition, eosinophilic esophagitis, is characterised by [...]

  • Drop in Covid-19 vaccine demand swings Oxford Biomedica to a loss

    September 15, 2022

    A drop in Covid-19 vaccine demand and manufacturing has swung British biotech firm Oxford Biomedica to a revenue loss in the half of the year. The London-listed firm, which worked with AstraZeneca’s to produce its Covid-19 vaccine, has revenue slip more than 20 per cent to £64m in the six moths to 30 June, down [...]

  • AstraZeneca share price dips with investors ‘underwhelmed’ by diabetes drug

    August 30, 2022

    AstraZeneca’s share price has dipped into the red today, with investors “underwhelmed” by its diabetes and heart failure drug Fraxiga. The stock sank 1.8 per cent to 11,160p per share by early afternoon. However, the share price has grown 6.2 per cent over the past three months. ‘’Investors appear to have been underwhelmed by the [...]

  • City Moves: Who’s switching jobs in the Square Mile?

    August 23, 2022

    City A.M.’s Millie Turner provides a roundup of the most important hires and job moves across the City, every morning. Email citymoves@cityam.com to be featured. Knight Frank Property consultancy Knight Frank has appointed a new head of lettings in its King’s Cross office. Joining from the firm’s Canary Wharf office where he was a most recently an associate in the lettings team, [...]

  • GSK shares float above recent lows amid looming legal woes

    August 17, 2022

    British pharmaceutical giant GlaxoSmithKline (GSK) has been wrapped up with legal woes this week over recalled heartburn drug Zantac and a former AstraZeneca dealmaker – which have wiped billions off its market value. London-listed GSK’s shares have dipped into the red slightly today but remained above recent lows. However, the company has lost nearly eight [...]

  • UK government must wake up to clinical research slowdown, industry body warns

    July 31, 2022

    A slowdown in clinical research could hold Britain back in its bid to become a life sciences superpower, an industry body has warned. In a letter to Rishi Sunak and Liz Truss, the Association of the British Pharmaceutical Industry (ABPI) said “alarm bells” should be ringing across the government, the Sunday Telegraph reported. The letter [...]

  • £1.4bn booster results: AstraZeneca’s strong performance paves a runway for growth

    July 29, 2022

    Pharma giant AstraZeneca saw first half revenues rise by 48 per cent to $22.2bn, ignoring the impact of exchange rates, as the company saw growth in all divisions apart from Other Medicines. Excluding the impact of the Alexion acquisition, exchange rates, and other one-off costs, operating profit was 71 per cent higher at £1.4bn. This [...]

  • Oxford Biomedica extends deal with AstraZeneca to make Covid vaccines beyond 2022

    July 1, 2022

    Oxford Biomedica have inked a new three-year agreement to make AstraZeneca's COVID-19 vaccine beyond 2022.

Posts navigation

  • Previous
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • …
  • Page 20
  • Next

Trending Articles

  • James May: Top Gear's future and my real relationship with Jeremy Clarkson

  • Investment slump amid higher interest rates risks finally sparking UK recession

  • Pound on course for highest level against US dollar in over a year, City analysts bet

  • House prices: London and south east falling faster than rest of the country

Subscribe

Subscribe to the City A.M. newsletter to have our top stories delivered directly to your inbox.

Subscribe
  • About us
  • Advertising
  • Contact
  • Terms & Conditions
  • Privacy Policy
  • News
  • Markets & Economics
  • Opinion
  • Jobs and Money
  • Unwind
  • Crypto A.M.
  • The Punter
  • COP 26
  • Awards 2023

Follow us for breaking news and latest updates

  • Newsletters
  • Latest paper
  • Advertising
  • CryptoAM.io
  • Awards
  • About
  • Tickets
Copyright 2023 City A.M. Limited